Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +38.61%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +36.94%
#4 OriginTrail OriginTrail +22.27%
#5 ApeX ApeX +19.21%
#6 UnifAI Network UnifAI Network +17.65%
#7 Morpho Morpho +17.47%
#8 龙虾 (Lobster) 龙虾 (Lobster) +16.01%
#9 Non-Playable Coin Non-Playable Coin +15.71%
#10 Pendle Pendle +14.97%
Coin of the day
Smilek to the Bank Smilek to the Bank
Settings
Language
ENGLISH
Currency
USD
Theme
Polaryx Therapeutics, Inc. Common Stock Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc. Common Stock

PLYX
Rank in Stocks #21586
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to... Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Share Price
$2.10
Last synced: 2026-08-21
Market Cap
$104.43M
Change (1 day)
-2.10%
Change (1 year)
-
Country
US
Trade Polaryx Therapeutics, Inc. Common Stock (PLYX)

Category

Healthcare
P/E ratio for Polaryx Therapeutics, Inc. Common Stock (PLYX)
P/E ratio as of 2026 TTM: 0
According to Polaryx Therapeutics, Inc. Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Polaryx Therapeutics, Inc. Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.